Fastest Growing Stocks
BLLN is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
BILLIONTOONE INC CL A (BLLN) Stock Price & Overview
NASDAQ:BLLN • US0901681058
Current stock price
86.97 USD
+7.54 (+9.49%)
Last:
The current stock price of BLLN is 86.97 USD. Today BLLN is up by 9.49%. In the past month the price increased by 14.43%.
BLLN Key Statistics
1-Month Range67 - 94.88
Current BLLN stock price positioned within its 1-month range.
- Market Cap
- 3.998B
- P/E
- 621.21
- Fwd P/E
- 178.54
- EPS (TTM)
- 0.14
- Dividend Yield
- N/A
BLLN Stock Performance
Today
+9.49%
1 Week
+10.51%
1 Month
+14.43%
3 Months
-0.69%
Longer-term
6 Months N/A
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
BLLN Stock Chart
BLLN Stock Screens
BLLN currently appears in the following ChartMill screener lists.
BLLN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to BLLN.
Chartmill TA Rating
Chartmill Setup Rating
BLLN Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to BLLN. While BLLN has a great health rating, there are worries on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BLLN Earnings
On March 4, 2026 BLLN reported an EPS of 0.11 and a revenue of 96.05M. The company beat EPS expectations (27.08% surprise) and beat revenue expectations (8.04% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateMar 4, 2026
PeriodQ4 / 2025
EPS Reported$0.11
Revenue Reported96.053M
EPS Surprise 27.08%
Revenue Surprise 8.04%
BLLN Forecast & Estimates
14 analysts have analysed BLLN and the average price target is 125.29 USD. This implies a price increase of 44.06% is expected in the next year compared to the current price of 86.97.
For the next year, analysts expect an EPS growth of 198.71% and a revenue growth 47.74% for BLLN
Analysts
Analysts84.29
Price Target125.29 (44.06%)
EPS Next Y198.71%
Revenue Next Year47.74%
BLLN Groups
Sector & Classification
BLLN Financial Highlights
Over the last trailing twelve months BLLN reported a non-GAAP Earnings per Share(EPS) of 0.14. The EPS increased by 114.79% compared to the year before.
Income Statements
Revenue(TTM)305.11M
Net Income(TTM)2.92M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.96% | ||
| ROA | 0.46% | ||
| ROE | 0.61% | ||
| Debt/Equity | 0.12 |
Chartmill High Growth Momentum
EPS Q2Q%103.94%
Sales Q2Q%-37.05%
EPS 1Y (TTM)114.79%
Revenue 1Y (TTM)99.97%
BLLN Ownership
Ownership
Inst Owners28.08%
Shares45.97M
Float20.27M
Ins Owners19.11%
Short Float %8.1%
Short Ratio5.35
BLLN Competitors/Peers
The largest stocks on the US markets in the "Health Care Services" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 10.58 | 99.068B | ||
| CI | THE CIGNA GROUP | 8.96 | 73.466B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 99.52 | 30.143B | ||
| LH | LABCORP HOLDINGS INC | 14.62 | 22.247B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.42 | 21.585B | ||
| GH | GUARDANT HEALTH INC | N/A | 11.853B | ||
| DVA | DAVITA INC | 10.57 | 9.88B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 30.1 | 9.131B | ||
| HIMS | HIMS & HERS HEALTH INC | 53.34 | 6.569B | ||
| CHE | CHEMED CORP | 16 | 5.619B | ||
| RDNT | RADNET INC | 88.42 | 4.687B | ||
| OPCH | OPTION CARE HEALTH INC | 15.13 | 4.524B |
Related stock screener links
View all stocks in the Health Care Services Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BLLN
Company Profile
BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. The company is headquartered in Menlo Park, California and currently employs 713 full-time employees. The company went IPO on 2025-11-06. The firm's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. The company applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
Company Info
IPO: 2025-11-06
BILLIONTOONE INC CL A
1035 O'brien Drive
Menlo Park CALIFORNIA US
Employees: 713
Phone: 13025310855
BILLIONTOONE INC CL A / BLLN FAQ
What does BILLIONTOONE INC CL A do?
BillionToOne, Inc. is a next-generation molecular diagnostics company on a mission to create powerful and accurate tests that are accessible to all. The company is headquartered in Menlo Park, California and currently employs 713 full-time employees. The company went IPO on 2025-11-06. The firm's proprietary molecular counting platform is designed to detect and measure deoxyribonucleic acid (DNA) molecules at a single-count level to help improve disease detection. The company applies the proprietary technology to non-invasive prenatal screening (Prenatal) and liquid biopsy (Oncology). Its Quantitative Counting Templates (QCTs), power its ability to detect and measure tiny and sparse disease-related DNA fragments, or molecules, at the single base-pair level. These include pregnancy-related DNA that code for recessively inherited conditions such as sickle cell disease and cystic fibrosis and ctDNA in the case of cancer. Its prenatal products include UNITY Complete, UNITY Fetal Risk Screen, UNITY Aneuploidy Screen, UNITY Fetal RhD NIPT, UNITY Fetal Antigen NIPT, and UNITY Fetal Antigen CTA NIPT. Its oncology products include Northstar and Northstar Select.
Can you provide the latest stock price for BILLIONTOONE INC CL A?
The current stock price of BLLN is 86.97 USD. The price increased by 9.49% in the last trading session.
Does BLLN stock pay dividends?
BLLN does not pay a dividend.
How is the ChartMill rating for BILLIONTOONE INC CL A?
BLLN has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for BILLIONTOONE INC CL A?
The Revenue of BILLIONTOONE INC CL A (BLLN) is expected to grow by 47.74% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is BILLIONTOONE INC CL A worth?
BILLIONTOONE INC CL A (BLLN) has a market capitalization of 4.00B USD. This makes BLLN a Mid Cap stock.